A Randomized, Double-Masked, Placebo-Controlled Study to Assess the Efficacy and Safety of REGN5713-5715 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Birch Pollen Allergy
Latest Information Update: 01 Oct 2024
At a glance
- Drugs REGN 5713 5715 (Primary)
- Indications Tree pollen hypersensitivity
- Focus Registrational; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 01 Oct 2024 New trial record